回盛生物：上半年从靶动物分类来看，猪用药品收入占比约为80%

Core Insights - The company has reported a significant increase in the sales revenue of its raw material pharmaceutical segment, which has risen by 15 percentage points compared to the same period last year [1] Group 1: Business Performance - The raw material pharmaceutical business now constitutes a larger share of the company's overall revenue due to the deepening of its integrated raw material and formulation strategy [1] - In the veterinary formulation segment, the company is not only consolidating its advantages in the pig medicine business but is also actively expanding into poultry, aquaculture, and ruminant sectors, resulting in substantial revenue growth across these product lines [1] - Revenue from pig medicines accounts for approximately 80% of the total revenue from targeted animal categories [1]